Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
Sondak
Vernon K
VK
H Lee Moffitt Cancer Center and University of South Florida College of Medicine, Tampa, FL 33612, USA. Electronic address: vernon.sondak@moffitt.org.
Flaherty
Lawrence E
LE
Karmanos Cancer Institute and Wayne State University School of Medicine, MI, Detroit, USA.
D000998:Antiviral Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D011092:Polyethylene Glycols; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b